ESC 2019 A stepped-wedge cluster randomized controlled trial showed that a salt-substitution strategy in 6 villages in Peru lowered blood pressure and reduced incidence of hypertension by half.
ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.
Download the EPCCS Practical Guidance Document, which provides a brief scientific background on the need for and practical guidance on management of hypertension, including when to start treatment and which blood pressure target should be used for a given patient. The document focusses on challenges faced in clinical reality.
In a large cohort study of 1.3 million participants, both systolic and diastolic hypertension were associated with composite of MI, ischemic stroke and hemorrhagic stroke, independent of thresholds defining hypertension.
ESC HF 2019 Addition of patiromer to spironolactone showed that a higher percentage of patients remained on spironolactone vs. those on placebo and spironolactone at the start, with no difference between HF or non-HF.
An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.
EPCCS 2019 Read impressions of the updates on stroke prevention in AF, hypertension, HF and CV risk in diabetes, with emphasis on challenges faced in patients with multimorbidities.
Profs. McManus and Hobbs consider the latest recommendations and insights on how to diagnose elevated blood pressure and when to initiate treatment.
EPCCS 2019 Slides prepared and presented by prof. Richard McManus - Oxford, UK, here offered as an educational service.
ACC 2019 The randomized INFINITY trial showed a reduction in accrual of subcortical white matter disease in older people treated to 130 vs. 145 mmHg, but that did not improve mobility and cognitive function.
The AHA has published a scientific statement on blood pressure measurements in humans to update findings released in the 2005 version.
A study with representative US citizens showed similar trends for most CV risk factors between men and women from 2001 to 2016, with the exception of BMI and total cholesterol, and sex differences for control of hypertension, diabetes and dyslipidemia.